GlassScriptPhysician profile
Suvesh Chandiok
NPI 1235112608
$70,915.19
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33K · 2020: $18K · 2021: $9,649 · 2022: $11K · 2023: $31.03 · 2024: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $269.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $268.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $34,445.48 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17,042.47 | 2019-2021 | |
| Lilly USA, LLC | $13,987.30 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $2,540.60 | 2019 | |
| Sanofi-Aventis U.S. LLC | $2,204.29 | 2019 | |
| Corcept Therapeutics | $261.74 | 2022-2024 | Korlym |
| Tandem Diabetes Care, INC. | $147.68 | 2020-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Shire North American Group INC | $89.70 | 2019 | |
| Mannkind Corporation | $83.14 | 2019-2021 | |
| Abbott Laboratories | $62.79 | 2019 | |
| Recordati_rare_diseases_inc. | $21.17 | 2021 | |
| Becton, Dickinson and Company | $17.50 | 2019 | |
| Ibsa Pharma INC. | $11.33 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suvesh Chandiok listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.